EGFR and non-small cell lung carcinoma: Identifying patients at greater risk might be useful in clinical practice when more treatment options are available (e.g., first-line treatment for EGFR-positive NSCLC), and tailoring anticancer treatment based on ctDNA would avoid unnecessary toxicity for patients, as well as unnecessary societal toxicities.